Slide 1: Interim Results for the six months ended 30 June 2024
Transforming cancer care with the first FDA cleared medical device for the capture and harvest of circulating tumour cells Interim Results for the six months ended 30 June 2024 Andrew Newland and Ian Griffiths 26 September 2024
Slide 2: Legal Disclaimer
LSE AIM:AGL Legal Disclaimer This presentation has been prepared by ANGLE plc (the “Company”). By attending this presentation and/or reviewing the slides you agree to be abound by the following conditions. The presentation slides which follow this notice and the oral presentation of which it forms p
Slide 3: Large Pharma strategy in place
Large Pharma strategy in place • Next generation blockbuster drugs need companion diagnostics (new classes of drugs: ADCs, DDR inhibitors, immunotherapy combinations) • Clonal evolution of cancer critical to disease progression requires real-time non-invasive assessment (simple blood test) • Large p
Slide 4: First Half Highlights
First Half Highlights Half year Post period end • Three large Pharma contracts secured • All three large pharma contracts progressing – Eisai: HER2 breast cancer well towards revenue expansion – AstraZeneca: DDR multiple cancers • Fourth pharma services contract agreed with Recursion Pharmaceuticals
Slide 5: Financial Results for the six months ended 30 June 2024
Financial Results for the six months ended 30 June 2024 Six months ended Six months ended Year ended 30 June 30 June 31 December Highlights 2024 2023 2023 £'000 £'000 £'000 • Planned operating expenditure (cash) of £7.5 million, reduced by 13% Statement of Comprehensive Income Revenue 1,034 1,196 2,
Slide 6: Large Pharma strategy revenue build
Large Pharma strategy revenue build • Assay development and pilot studies c. £200,000 Pharma companion diagnostic pathway - indicative only Revenue Potential Year 1 Phase 1 £0.2m to £0.7m Years 2-3 Phase 2 £1.2m to £3.6m Years 4-5 Phase 3 £15m to £45m Year 6 onwards Companion Diagnostic £20m to £100
Slide 7: Eisai: HER2 breast cancer. ADC a new class of drug
Eisai: HER2 breast cancer. ADC a new class of drug Global Japanese pharma company • Revenues >£3.7 billion3 >10,000 employees • >70 active oncology clinical trials >50,000 participants • HER2 targeting antibody-drug conjugate (ADC) being co-developed by Eisai and Bliss Biopharmaceutical Co., Ltd as
Slide 8: AstraZeneca: DDR multiple cancers
AstraZeneca: DDR multiple cancers Global pharma company with major oncology focus contributing to 39% of total product sales1 " It is through our science- • 459 active, interventional cancer clinical trials in 139,000 patients driven approach in targeting • Therapies targeting DNA Damage Response fo
Slide 9: AstraZeneca: AR prostate cancer
AstraZeneca: AR prostate cancer AR plays a pivotal role in Androgen Receptor (AR) detection assay for use in prostate cancer, especially castration-resistant prostate AstraZeneca’s prostate cancer studies cancer (CRPC). • 12-month development phase worth £550,000 CRPC is incurable and can • ANGLE's
Slide 10: Recursion Pharmaceuticals
Recursion Pharmaceuticals • Clinical-stage biotechnology company leveraging technology, including machine learning and AI, to industrialise drug discovery • Five research programmes in clinical development, with a further two in preclinical development and 12 in early discovery • Agreement signed in
Slide 11: Other biopharma customers
Other biopharma customers © ANGLE plc 2024 11
Slide 12: NuProbe: NGS pan-cancer gene panel
NuProbe: NGS pan-cancer gene panel “CTCs represent a transformative biomarker in precision oncology, offering extraordinary opportunities to translate scientific discoveries into • Cutting-edge genomics and molecular diagnostics company tangible improvements in patient care… • Option to exclusive gl
Slide 13: Growing body of third-party evidence
Growing body of third-party evidence • FDA and EU clearance expected to give ANGLE first mover advantage As of September 2024 in non-invasive repeat testing of intact cancer cells Clinically relevant biomarkers 88% published in including: • >260 Parsortix systems in use EGFR BRAF 40 high impact jour
Slide 14: Outlook
Outlook • Good progress with existing three large pharma contracts with future revenue growth potential • Multiple cross-sell opportunities with existing large pharma customers • Multiple additional large pharma and corporate contracts under discussion • Molecular assay for dual analysis of CTCs and
Slide 15: ANGLE plc contact details
ANGLE plc 10 Nugent Road Surrey Research Park Guildford GU2 7AF United Kingdom angleplc.com © ANGLE plc 2024 15